Enhancement of neutralizing efficacy by combining three monoclonal antibodies to human interferon-alpha. 1991

P Kontsek, and L Borecký, and M Novák, and E Kontseková, and I Máciková
Institute of Virology, Slovak Academy of Sciences, Bratislava, Czech.

Three murine monoclonal antibodies (mAb) directed to distinct epitopes on recombinant human interferon (IFN)-alpha 1, and three mAb recognizing distinct epitopes on recombinant human interferon (IFN) alpha 1, and three mAb recognizing distinct epitopes on recombinant human IFN-alpha sc, were studied by IFN-neutralizing assays. The efficacy of neutralization of the anti-viral and the anti-proliferative activities of IFN-alpha 1, or IFN-alpha 2c, by the specific antibodies used, individually or in combination, were evaluated. In comparison with single mAb, the mixtures of three mAb against IFN-alpha 1 or three mAb against IFN-alpha 2c were capable of neutralizing more than 10-times larger amounts of IFN-alpha 1 and alpha 2c, respectively. The strong potentiation of the neutralization efficacy resulting from mixing different mAb was demonstrated by neutralization of the anti-viral as well as the anti-proliferative activities of both recombinant IFN. The neutralization experiments support the interpretation that the observed potentiation results from simultaneous interaction of anti-IFN mAb with different epitope specificity.

UI MeSH Term Description Entries
D007370 Interferon Type I Interferon secreted by leukocytes, fibroblasts, or lymphoblasts in response to viruses or interferon inducers other than mitogens, antigens, or allo-antigens. They include alpha- and beta-interferons (INTERFERON-ALPHA and INTERFERON-BETA). Interferons Type I,Type I Interferon,Type I Interferons,Interferon, Type I,Interferons, Type I
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D002455 Cell Division The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION. M Phase,Cell Division Phase,Cell Divisions,Division Phase, Cell,Division, Cell,Divisions, Cell,M Phases,Phase, Cell Division,Phase, M,Phases, M
D004306 Dose-Response Relationship, Immunologic A specific immune response elicited by a specific dose of an immunologically active substance or cell in an organism, tissue, or cell. Immunologic Dose-Response Relationship,Relationship, Immunologic Dose-Response,Dose Response Relationship, Immunologic,Dose-Response Relationships, Immunologic,Immunologic Dose Response Relationship,Immunologic Dose-Response Relationships,Relationship, Immunologic Dose Response,Relationships, Immunologic Dose-Response
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000911 Antibodies, Monoclonal Antibodies produced by a single clone of cells. Monoclonal Antibodies,Monoclonal Antibody,Antibody, Monoclonal
D000918 Antibody Specificity The property of antibodies which enables them to react with some ANTIGENIC DETERMINANTS and not with others. Specificity is dependent on chemical composition, physical forces, and molecular structure at the binding site. Antibody Specificities,Specificities, Antibody,Specificity, Antibody
D000939 Epitopes Sites on an antigen that interact with specific antibodies. Antigenic Determinant,Antigenic Determinants,Antigenic Specificity,Epitope,Determinant, Antigenic,Determinants, Antigenic,Specificity, Antigenic
D014721 Vesicular stomatitis Indiana virus The type species of VESICULOVIRUS causing a disease symptomatically similar to FOOT-AND-MOUTH DISEASE in cattle, horses, and pigs. It may be transmitted to other species including humans, where it causes influenza-like symptoms. Vesicular stomatitis-Indiana virus

Related Publications

P Kontsek, and L Borecký, and M Novák, and E Kontseková, and I Máciková
April 1987, Hybridoma,
P Kontsek, and L Borecký, and M Novák, and E Kontseková, and I Máciková
December 1984, The Journal of general virology,
P Kontsek, and L Borecký, and M Novák, and E Kontseková, and I Máciková
September 2016, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research,
P Kontsek, and L Borecký, and M Novák, and E Kontseková, and I Máciková
January 1985, Voprosy virusologii,
P Kontsek, and L Borecký, and M Novák, and E Kontseková, and I Máciková
April 1983, Clinical and experimental immunology,
P Kontsek, and L Borecký, and M Novák, and E Kontseková, and I Máciková
January 1986, Ciba Foundation symposium,
P Kontsek, and L Borecký, and M Novák, and E Kontseková, and I Máciková
April 1988, Journal of biological response modifiers,
P Kontsek, and L Borecký, and M Novák, and E Kontseková, and I Máciková
May 1987, The Journal of general virology,
P Kontsek, and L Borecký, and M Novák, and E Kontseková, and I Máciková
February 1984, Clinical immunology and immunopathology,
P Kontsek, and L Borecký, and M Novák, and E Kontseková, and I Máciková
June 2007, Neurology,
Copied contents to your clipboard!